WO1999044587A1 - Apparatus and method for diluting nasal sprays containing addictive compounds - Google Patents
Apparatus and method for diluting nasal sprays containing addictive compounds Download PDFInfo
- Publication number
- WO1999044587A1 WO1999044587A1 PCT/US1999/004446 US9904446W WO9944587A1 WO 1999044587 A1 WO1999044587 A1 WO 1999044587A1 US 9904446 W US9904446 W US 9904446W WO 9944587 A1 WO9944587 A1 WO 9944587A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- spray
- diluent
- indicia
- container
- level
- Prior art date
Links
- 239000007922 nasal spray Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 30
- 150000001875 compounds Chemical class 0.000 title claims abstract description 14
- 238000007865 diluting Methods 0.000 title claims abstract description 8
- 239000007921 spray Substances 0.000 claims abstract description 31
- 229940097496 nasal spray Drugs 0.000 claims abstract description 30
- 239000003085 diluting agent Substances 0.000 claims abstract description 25
- 230000000779 depleting effect Effects 0.000 claims abstract description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229960001528 oxymetazoline Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012895 dilution Substances 0.000 abstract description 3
- 238000010790 dilution Methods 0.000 abstract description 3
- 206010012335 Dependence Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000013459 approach Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002650 habitual effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000133 nasal decongestant Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 208000027744 congestion Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960000833 xylometazoline Drugs 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960005016 naphazoline Drugs 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229940064713 other nasal preparations in atc Drugs 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0468—Liquids non-physiological
Definitions
- This invention relates to an apparatus and method for diluting nasal sprays containing
- nasal preparations available over-the-counter contain compounds such as
- xylometazoline naphazoline, phenylephrine and pharmaceutically acceptable salts thereof.
- Nasal decongestants containing oxymetazoline offer fast and effective relief
- oxymetazoline has undesired side-effects, one of which
- nasal sprays remain symptomatic beyond the recommended dosage period , and despite warnings
- compositions for treating addiction to drugs, alcohol, and tobacco, such as
- the invention comprises an apparatus and method for diluting nasal
- the apparatus comprises a container holding a volume of nasal spray having at least one
- the indicia is a mark, sign, or symbol signifying
- indicia is a horizontal line around the circumference of the container.
- the apparatus has a second indicia showing the initial volume of the spray in the container. The level to which the nasal
- the spray can either be administered or removed to the pre ⁇
- Means are provided for depleting the nasal spray, such as an
- the depleted volume of the nasal spray is replenished with
- a diluent such as sodium chloride solution.
- Sodium chloride is employed as a diluting agent
- nasal spray using an eye dropper, syringe, or other similar device using an eye dropper, syringe, or other similar device.
- the method comprises the successive dilution of the nasal spray using an apparatus
- the nasal spray is depleted to the pre-selected level and
- a diluent such as sodium chloride solution.
- distilled water is
- the indicia is located at the level showing 15% from the total initial
- the user can repeat the steps approximately thirty times, until the solution
- FIG. 1 is a perspective view of the apparatus shown with two indicia.
- FIG 2 is a perspective view of the apparatus shown with one indicia.
- FIG. 1 The preferred embodiment of the invention 10 is illustrated in FIG. 1 .
- the container 12
- the container 12 is either a
- nasal spray 14 contains 0.05% oxymetazoline hydrochloride, but can contain other formulations
- the container 12 has a first indicia 18 and a second indicia 20 around the periphery.
- First indicia 18 is preferably located at the level showing 15% depletion of the total initial
- Second indicia 20 is located at the level showing the initial total volume
- the level of the nasal spray 14 reaches the first indicia 18, the user is prompted to add diiuent. The user can then either add
- sodium chloride solution or distilled water as diluent.
- Diluent can be added by way of an eye dropper or syringe, being careful
- the second indicia 20 aids the user when replenishing the depleted amount of nasal spray
- container 12 can be emptied to the level of the first indicia 18, by either administration or
- the diluent can then be added on a daily basis, as opposed to an "as needed” or
- FIG. 2 shows an alternate embodiment of the invention.
- One indicia 1 8 is shown on the
- indicia 18 indicates the level at which the diluent should be added. The user can employ the
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99908593A EP1023046A4 (en) | 1998-03-02 | 1999-03-01 | Apparatus and method for diluting nasal sprays containing addictive compounds |
CA002312744A CA2312744C (en) | 1998-03-02 | 1999-03-01 | Apparatus and method for diluting nasal sprays containing addictive compounds |
AU27988/99A AU2798899A (en) | 1998-03-02 | 1999-03-01 | Apparatus and method for diluting nasal sprays containing addictive compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/033,252 | 1998-03-02 | ||
US09/033,252 US5988870A (en) | 1998-03-02 | 1998-03-02 | Apparatus and method for diluting nasal sprays containing addictive compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999044587A1 true WO1999044587A1 (en) | 1999-09-10 |
Family
ID=21869364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/004446 WO1999044587A1 (en) | 1998-03-02 | 1999-03-01 | Apparatus and method for diluting nasal sprays containing addictive compounds |
Country Status (5)
Country | Link |
---|---|
US (1) | US5988870A (en) |
EP (1) | EP1023046A4 (en) |
AU (1) | AU2798899A (en) |
CA (1) | CA2312744C (en) |
WO (1) | WO1999044587A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH702425A1 (en) * | 2009-12-28 | 2011-06-30 | Innostarter Ag | Container for receiving and Abgae a liquid and / or dissolved in particular pharmaceutical active substance |
DE102010042360A1 (en) | 2010-10-12 | 2012-04-12 | Andreas Charap | Nasal spray bottle, useful for dilution of drug to be administered, and for preventing or treating rhinitis medicamentosa, preferably withdrawal rhinitis medicamentosa, comprises a spray nozzle and a two chamber system |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6712803B1 (en) * | 1999-08-11 | 2004-03-30 | Howard Paritsky | Drug dispensing system |
FR2832329B1 (en) * | 2001-11-20 | 2004-11-19 | Valois Sa | SIDE OPERATION SPRAYING DEVICE |
US7714011B2 (en) * | 2002-09-13 | 2010-05-11 | Zicam, Llc | Compositions to reduce congestion and methods for application thereof to the nasal membrane |
US20040235807A1 (en) * | 2003-05-21 | 2004-11-25 | Weinrich Karl P. | Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea |
US20160144083A1 (en) * | 2014-11-24 | 2016-05-26 | Dai Vinh | Nasal aspirator device |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272149A (en) * | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
US5688804A (en) * | 1992-08-04 | 1997-11-18 | Pfizer Inc. | 3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US53790A (en) * | 1866-04-10 | Improvement in apparatus for administering medicines | ||
US2564400A (en) * | 1949-10-29 | 1951-08-14 | Sharp & Dohme Inc | Atomizer |
US3140052A (en) * | 1963-01-21 | 1964-07-07 | Richardson Merrell Inc | Spray nozzle comprising a base member and a cap |
US4564129A (en) * | 1983-01-27 | 1986-01-14 | Hoechst-Roussel Pharmaceuticals Inc. | Dosage dispensing unit |
-
1998
- 1998-03-02 US US09/033,252 patent/US5988870A/en not_active Expired - Lifetime
-
1999
- 1999-03-01 AU AU27988/99A patent/AU2798899A/en not_active Abandoned
- 1999-03-01 CA CA002312744A patent/CA2312744C/en not_active Expired - Fee Related
- 1999-03-01 WO PCT/US1999/004446 patent/WO1999044587A1/en active Application Filing
- 1999-03-01 EP EP99908593A patent/EP1023046A4/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272149A (en) * | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
US5688804A (en) * | 1992-08-04 | 1997-11-18 | Pfizer Inc. | 3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH702425A1 (en) * | 2009-12-28 | 2011-06-30 | Innostarter Ag | Container for receiving and Abgae a liquid and / or dissolved in particular pharmaceutical active substance |
DE102010042360A1 (en) | 2010-10-12 | 2012-04-12 | Andreas Charap | Nasal spray bottle, useful for dilution of drug to be administered, and for preventing or treating rhinitis medicamentosa, preferably withdrawal rhinitis medicamentosa, comprises a spray nozzle and a two chamber system |
Also Published As
Publication number | Publication date |
---|---|
CA2312744A1 (en) | 1999-09-10 |
CA2312744C (en) | 2007-03-27 |
EP1023046A1 (en) | 2000-08-02 |
US5988870A (en) | 1999-11-23 |
EP1023046A4 (en) | 2007-12-26 |
AU2798899A (en) | 1999-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4546699B2 (en) | Spray equipment | |
US5941241A (en) | Method and device for organizing and coordinating the combined use of topical aerosols for the treatment of respiratory disorders | |
US8758816B2 (en) | Compositions comprising azelastine and methods of use thereof | |
EP2335759B1 (en) | Apparatus for nasal rinse | |
JP5632284B2 (en) | Compositions and methods for sedation and analgesia during treatment using oral transmucosal dosage forms | |
US20030077300A1 (en) | System and method for intranasal administration of opioids | |
US6571790B1 (en) | Method and device for organizing and coordinating the combined use of liquid medications for continuous nebulization for the treatment of respiratory disorders | |
US5806723A (en) | Device for lavaging | |
US8398580B2 (en) | Methods and apparatus for treating rhinitis | |
EP1370212A1 (en) | System and method for intranasal administration of lorazepam | |
US20190262263A1 (en) | Compositions, devices and methods for the treatment of opioid-receptor-mediated conditions | |
JP2002541921A (en) | Spray dispenser for opioid antagonists | |
WO1992005781A1 (en) | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form | |
WO2005020906A2 (en) | Intranasal opioid compositions | |
WO2010065547A1 (en) | Inhalation delivery methods and devices | |
CA2312744C (en) | Apparatus and method for diluting nasal sprays containing addictive compounds | |
CA2519175A1 (en) | A method of treating a systemic disease | |
US6294178B1 (en) | Method and device for coordinating topical and oral sinusitis treatments | |
WO2004024187A2 (en) | Compositions to reduce congestion and methods for application thereof to the nasal membrane | |
WO2000018379A2 (en) | Pharmaceutical preparation for use in a method to abate the use of tobacco by humans | |
US6712803B1 (en) | Drug dispensing system | |
US20090221987A1 (en) | Portable sinus and throat cleansing system and method | |
CA2330654A1 (en) | A device for organizing the combined use of topical aerosols and oral medication | |
US6932978B2 (en) | Double-headed, closed-mouth cough suppressant and cold relief device | |
US20240024232A1 (en) | Naloxone formulations for sublingual and/or buccal administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999908593 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2312744 Country of ref document: CA Ref country code: CA Ref document number: 2312744 Kind code of ref document: A Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1999908593 Country of ref document: EP |